Medscape frames retatrutide demand as pitting physicians against patients

A commentary published August 19, 2026 on Medscape describes a growing tension in exam rooms: patients who have read headlines about retatrutide's weight-loss results are asking their doctors for the drug, even though it is not approved anywhere and is not for sale by Eli Lilly, the company developing it ^[1].

Retatrutide is an investigational drug that acts on three hormone pathways at once — GLP-1, GIP and glucagon. By mid-2026, Lilly had completed all four core TRIUMPH phase 3 trials plus a diabetes-focused trial called TRANSCEND. The results were notable: average body weight loss of roughly 28% to 30% at the highest doses, along with improvements in cholesterol, blood pressure, sleep apnea severity and knee osteoarthritis pain. The safety profile looked similar to semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). Lilly is expected to file for FDA approval in the first quarter of 2027 ^[1].

Until then, the only legal routes to the drug are enrollment in an ongoing Lilly trial or a narrow expanded access program meant for people with severe, treatment-resistant obesity and life-threatening related conditions. To even apply, a patient must be at least 18, have obesity that hasn't responded to the highest tolerable dose of an already-approved medication, have at least two serious or life-threatening obesity-related conditions under active medical management, and be unable to join a trial for retatrutide or a similar drug ^[1].

According to the commentary, clearing that bar is only the start. Lilly's expanded access office must issue an authorization letter tied to the drug's investigational new drug application — a step described as the longest and least predictable, with no guaranteed timeline and no public information from Lilly on approval rates, treatment duration, or who pays for the drug and its monitoring. The physician must separately file FDA Form 3926. Then an institutional review board must sign off, a process meant to be fast — 24 to 48 hours when a doctor requests expedited chair concurrence — but it is still a separate, independent gate ^[1]. Because each step runs on its own timeline with no appeals process and no way to run them in parallel, the author writes that the wait for a single authorized dose can stretch to the better part of a year ^[1].

Separately, Lilly has begun legal action to shut down unauthorized sources of the drug. On August 12, 2026, the company filed six lawsuits in California and Texas against peptide sellers, a compounding pharmacy and a medical spa — Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide — alleging they sold or marketed unapproved retatrutide products for human use, including some labeled "research use only." Analysts cited in that report project retatrutide could generate roughly $5.3 billion in revenue by 2030 ^[2].

Why it matters for patients

For patients with severe obesity and serious health complications, the practical reality right now is that retatrutide is essentially unavailable outside a clinical trial. The expanded access pathway that exists on paper involves three separate gatekeepers — Lilly, the FDA, and an institutional review board — any one of which can stall or stop a request, with no clear answer on cost or how long treatment would last if approved ^[1]. Meanwhile, products marketed online as retatrutide are not verified, not approved, and now the subject of active lawsuits alleging unlawful sale, which raises questions about what is actually being sold and its safety ^[2]. The Medscape commentary frames this gap as one that falls hardest on individual physicians, who have no control over the timelines set by any of the three approval steps ^[1].

What happens next

Lilly is expected to submit an FDA application for retatrutide in the first quarter of 2027 ^[1]. Until an approval decision is made, expanded access and trial enrollment remain the only sanctioned ways to obtain the drug, and Lilly's litigation against unauthorized sellers is ongoing ^[1][2].